Editorial
Luteinizing hormone-releasing hormone analogues and hormone ablation for prostate cancer
Controversies regarding screening for prostate cancer
Is the era of prostate-specific antigen over?
Current prostate cancer
Chemoprevention of prostate cancer
Chemotherapy of premalignant lesions
European Study of Radical Prostatectomy
Active surveillance vs radical prostatectomy
How to preserve potency and continence in localized prostate cancer
Definition and management of prostate-specific antigen recurrence after local therapy
Is hormone ablation still the right choice for advanced prostate cancer?
Adjuvant treatment to surgery
Adjuvant treatment to radiation
Multiple intracrine hormonal targets in the prostate
Molecular aspects of hormone-independent prostate cancer
Hormone-refractory prostate cancer
Combination of somatostatin analogues and dexamethasone (antisurvival-factor concept) with luteinizing hormone-releasing hormone in androgen ablation-refractory prostate cancer with bone metastasis